Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab consolidation after concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2400082243Phase 2Recruiting
- Sponsor
- Jinhua Hospital of Zhejiang University
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Jinhua Hospital of Zhejiang University. Primary endpoints: Adverse events and Serious adverse events. Started Mar 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400082243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082243.